In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

As for Nuvaxovid, this standalone Novavax Covid-19 vaccine received its FDA approval in May, a regulatory decision that covers its use in those age 65 and older.

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...

Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.Biologics License Application approval triggers $175 million Sanofi milestone payment, with ...

Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine, albeit with new conditions.

The FDA approved NVAX's protein-based COVID vaccine, Nuvaxovid Biotech stock Novavax Inc (NASDAQ:NVAX) is skyrocketing today, up 26% at $8.48 at last glance, after the U.S. Food & Drug ...

About Nuvaxovid™ Nuvaxovid (NVX-CoV2705) is an updated version of Novavax's prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the JN.1 variant.